Wankomycyna i jej chemiczne modyfikacje

• Autorzy: Łakomiec A. , Samaszko J. , Madaj J.

Warianty tytułu

EN

Vancomycin and its chemical modifications

• Języki publikacji: PL

Abstrakty

EN

Antibiotics, such as penicillin or streptomycin, are substances produced by or derived from certain fungi or bacteria, that can destroy or inhibit the growth of other microorganisms. Antibiotics are widely used in the prevention and treatment of infectious diseases. Glycopeptide antibiotics are a class of antibiotic drugs. They consist of a glycosylated cyclic or polycyclic nonribosomal peptide. Important glycopeptide antibiotics include vancomycin, teicoplanin, ramoplanin, and decaplanin. This class of drugs inhibits the synthesis of cell walls in susceptible microbes by inhibiting peptidoglycan synthesis. Glycopeptides exhibit a narrow spectrum of activity as principally effective against gram positive cocci. They are the last line of effective defense against MRSA and multiresistant enterococci for patients who are critically ill. At the beginning of the 90' there started a large scale research program for finding glycopeptide antibiotics with optimized properties. These studes resulted in the discovery of the hemi-synthetic compounds (1996 oritavancin) which have lower toxicity than vancomycin.

Słowa kluczowe

PL

wankomycyna; glikopeptydy; oporność glikopeptydów

EN

vancomycin; glycopeptide; glycopeptide resistance

• Wydawca: Polskie Towarzystwo Chemiczne
• Czasopismo: Wiadomości Chemiczne
• Rocznik: 2007
• Tom: [Z] 61, 3-4
• Strony: 231--245
• Opis fizyczny: bibliogr. 37 poz., tab., wykr.

Twórcy

autor

Łakomiec A.

autor

Samaszko J.

autor

Madaj J.

• Wydział Chemii Uniwersytetu Gdańskiego, ul. J. Sobieskiego 18, 80-952 Gdańsk,

Bibliografia

• [1] D.T.W. Chu, J.J. Plattner, L. Katz, Journal of Medicinal Chemistry, 1996, 39, 3853.
• [2] Z. Markiewicz, Z.A. Kwiatkowski, Bakterie, Antybiotyki, Lekooporność. PWN, Warszawa 2001.
• [3] M.P. Lechevalier, H. Praser, D.P. Labeda, J.S. Ruan, Int. J. Sys. Bacteriol., 1986, 36, 29.
• [4] a) P.F. Wiley, K. Gerzon, E.H. Flynn, M.V. Sigal, Jr., O. Weave, U.C. Quarck, R.R. Chauvette, R. Monahan J. Am. Chem. Soc., 1957, 79, 6062; b) I. Paterson, M.M. Mansuri, Tetrahedron, 1958, 41, 3569; c) J.D. Smilack, W.R. Wilson, F.R. Cockerill III, Mayo Clin. Proc., 1999, 66, 1270; d) D.C. Brittain, Med. Clin. North Am., 1987, 71, 1147.
• [5] C.M. Harris, T.M. Harris, J. Am. Chem. Soc., 1982, 104, 4293.
• [6] R. Rocchi, L. Biondi, F. Filira, m. Golbo, Chimica oggi = chemistry today, 2003, 6, 17.
• [7] F.J. Schmitz, M.E. Jones, International Journal of Antimicrobial Agents, 997, 9, 1.
• [8] H. Kleinkauf, H. Von Dohren, Eur. J. Biochem., 1996, 236, 335.
• [9] E.A. Norris, I.N. Thalia, FEMS Microbiology Reviews, 2003, 26, 511.
• [10] C.T. Walsh, H.C. Losey, C.L. Freel Meyers, Biochemical Society, 2003, 31, 487.
• [11] K.C. Nicolaou, C.N.C. Boddy, S. Bräse, N. Winssinger., Angew. Chem. Int. Ed., 1999, 38, 2096.
• [12] D.A. Evans, M.R. Wood, B.W. Trotter, Angew. Chem., 1998, 110, 2864; Angew. Chem. Int. Ed., 1998, 37, 2700.
• [13] K.C. Nicolaou, H.J. Mitchell, N.F. Jain, T. Bando, R. Hughes, N. Wissinger, S. Natarajan, A.E. Koumbis., Chem. Eur. J., 1999, 5, 2648.
• [14] N. Miyaura, A. Suzuki, Chem. Rev., 1995, 95, 2457.
• [15] A. Suzuki, Pure Appl. Chem., 1985, 57, 1749.
• [16] A. Suzuki, Pure Appl. Chem., 1994, 66, 213.
• [17] K.C. Nicolaou, D. Vourloumis, N. Winssinger, P.S. Baran., Angew. Chem. Int. Ed., 2000, 39, 44.
• [18] A.T.Jr. Scheldon, Clin. Lab. Sci., 2005, 18, 170.
• [19] C.H. Wong, M.C. Bryan, Pure Appl. Chem., 2003, 75, 179.
• [20] K. Hiramatsu, Lancet Infections Diseases, 2001, 1, 147.
• [21] J. Van Heijenoon, Bacterial Cell Wall, edited by J.M. Ghuysen & R. Hakenbeck, Amsterdam, Science, 39.
• [22] D. Kahne, K. Leimkuhler, W. Lu, C. Walsh, Chem. Rev., 2005, 105, 425.
• [23] I.A. Holder, A.N. Neely, Burns, 1998, 24, 99.
• [24] M. Włodarczyk, Kosmos . Problemy Nauk Biologicznych, 2002, 51, 241.
• [25] J. Davies, Science, 1994, 264, 375.
• [26] H.C. Neu, Science, 1992, 257, 1064.
• [27] J. Potrykus, Kosmos . Problemy Nauk Biologicznych, 2002, 51, 331.
• [28] K. Hiramatsu, H. Hanaki, t. Ino, K. Jabuta, T. Oguri, F.C. Tenover, J. Antimicrob. Chemother., 1997, 40, 135.
• [29] D. Dzierżanowska, A. Pawińska, W. Kamińska, J. Patzer, Post. Mikrobiol., 2004, 43, 81.
• [30] S. Méndez-Álvarez, X. Pérez-Hernández, F.C. Martin, Internatt. Microbiol., 2000, 3, 71.
• [31] J. Halliday, D. McKeveney, C. Muldoon, P. Rajaratnam, W. Meutermans, Biochemical Pharmacology, 2006, 71, 957.
• [32] J.L. Pace, G. Yang, Biochemical Pharmacology, 2006, 71, 968.
• [33] A. Malabarba, R. Ciabatti, Current Medicinal Chemistry, 2001, 8, 1759.
• [34] T.I. Nicas, D.L. Mullen, J.E. Flokowitsch, D.A. Preston, N.J. Snyder, M.J. Zweifel, S.C. Wilkie, M.J. Rodriguez, R.C. Thompson, R.D.G. Cooper, Antimicrob. Agents Chemother., 1996, 40, 2194.
• [35] F. Van Bambeke, Current Opinion in Pharmacology, 2004, 4, 471.
• [36] Z. Shi, J.H. Griffin, J. Am. Chem. Soc., 1993, 115, 6482-6486.
• [37] U.N. Sundram, J.H. Griffin, J. Org. Chem., 1995, 60, 1102-1103.